Tag

level one
Intact Tendon

Fixing Rotator Cuff Tears with Bone Marrow Concentrate—Beating the Odds for an Intact Tendon at 10-Years – Part Two

In the previous post, I started reviewing a classic paper published by Dr. Philippe Hernigou and co-workers, entitled “Biological augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.” I will continue in this post by reporting on clinical outcomes from the study. Most importantly,...
Read More
Rotator Cuff

Fixing Rotator Cuff Tears with Bone Marrow Concentrate—Beating the Odds for an Intact Tendon at 10-Years – Part One

Dr. Philippe Hernigou published a paper in 2014 entitled “Biological augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.” I selected this paper to start my review of Dr. Hernigou’s extensive clinical study series on BMC therapy for orthopedic pathologies in part because it has...
Read More
Hernigou Treatment

Filling the FDA’s Gaps on BMC and Clinical Studies with the help of Dr. Hernigou

The past couple of posts (No Increased Cancer Risk from Your Autologous BMC Treatment and Making Sense of Your Environment—if You are a Stem Cell) have covered aspects of the puzzling and misleading article FDA personnel published in the New England Journal of Medicine (NEJM) last November. In particular, the authors complained about the lack...
Read More
Stem Cell

Making Sense of Your Environment—if You are a Stem Cell

In a previous post, I commented on a paper recently published in the New England Journal of Medicine (NEJM) in which FDA personnel expressed their dissatisfaction with the lack of solid, Level 1 clinical trials for the use of stem cell therapies by citing the lack of systematic recording of adverse events and a lack...
Read More
BMC

No Increased Cancer Risk from Your Autologous BMC Treatment

In the previous post, I commented on a paper recently published in the New England Journal of Medicine (NEJM) in which FDA personnel expressed their dissatisfaction with the lack of solid, Level 1 clinical trials for the use of stem cell therapies. Their concern quite naturally was on the lack of systematic recording of adverse...
Read More
Cell Therapy

FDA’s Broadside Against Cell Therapy

The New England Journal of Medicine recently published an article written by folks at the FDA on science-based approaches to regulating the apparently confusing world of stem cell therapy (View Article). The focus of the article was on describing how the FDA views “stem-cell (sic) therapy”: “Often, these cells (whether derived from autologous or allogeneic...
Read More
Treating Knee Osteoarthritis with Saline

Curious BMC and Saline Treatment Results for Patients With Bilateral Knee OA – Part Two

In the previous post, I had started my review of a paper published by Shapiro, et al., earlier this year (View Paper), in which they showed that treating a patient’s knee osteoarthritis with saline gave the same degree of pain relief as the use of bone marrow concentrate (BMC) in the other arthritic knee. Crazy,...
Read More
BMC and Saline Treatment Results

Curious BMC and Saline Treatment Results for Patients With Bilateral Knee OA – Part One

In a paper published earlier this year (View Paper ), Shapiro, et al. reported on the results obtained from a clinical study in which a patient’s bone marrow was concentrated (creating BMC) and injected into one of the patient’s arthritic knees, with the other knee being injected with sterile saline. It turns out that the...
Read More